1. Introduction {#s0005}
===============

Menadione, vitamin K3, is a synthetic compound that belongs to the class of lipid-soluble vitamins, which is converted to vitamin K2 in the gut ([@b0035]). Lipid-soluble vitamins are organic substances present in small amounts in foods, and they are essential to the functioning of the body as co-factors ([@b0090]). Vitamin K is a biologically active substance found in functional foods, which is required particularly in the mechanism of blood coagulation, where it is essential for the synthesis of prothrombin, besides being involved in the synthesis of proteins present in plasma, kidney and perhaps other tissues. Some studies on vitamin K2 have demonstrated growth inhibitory effects against various neoplastic cells and reduced risk of mutagenic events in rapid cell proliferation in the fetus and newborn ([@b0035]). Some studies report that lipid-soluble compounds modulate plasma membrane permeability in bacteria ([@b0095], [@b0020], [@b0080]). Therefore, menadione with its lipid-soluble nature may cause changes in the fluidity of the bacterial membrane, making it more permeable to substances, including antibiotics.

Cholesterol is a lipid component that is necessary for normal functioning of the body, and it plays an important role in the structure and function of the plasma membrane as well as organelle membranes. Also, it is involved in the synthesis of bile acids required for the absorption of lipids and lipid-soluble vitamins from the intestine, and participates in the synthesis of steroid hormones and vitamin E ([@b0065], [@b0050]).

Bacteria do not have cholesterol as part of their cytoplasmic membrane, nor ergosterol, a cholesterol derivative and lipid component of fungal membranes. Both sterols were used as complex lipid substances ([@b0100], [@b0125], [@b0060]) that can act on the fluid mosaic of the bacterial membrane, modifying its fluidity, for comparison with menadione with regard to effect on the bacterial plasma membrane.

Bacteria are simple organisms found in most natural environments, where the bacterial cell has several structures, some present only in certain species. An essential structure is the cytoplasmic membrane, which is responsible for numerous functions including DNA replication, enzyme secretion, biosynthesis of components, solute transport and energy production ([@b0105]). The cell wall is a structure that gives rigidity to many bacteria, and according to its constitution, bacteria are divided into two classes, Gram-positive and Gram-negative bacteria, the difference being mainly due to their permeability properties and surface components ([@b0130], [@b0105]; Pretto et al., 2005).

Bacterial infections are currently the focus of public health, mainly due to the significant growth of bacterial resistance. Infections caused by *Staphylococcus aureus* are the most common, showing a greater difficulty in treatment due to its resistance to various antibiotics ([@b0130]). The species *Pseudomonas aeruginosa* is the leading cause of nosocomial infections, attacking the skin, urinary tract, ear, and eye ([@b0075]). *Escherichia coli* are the most common species of the genus *Escherichia*, associated with severe urinary tract infections, meningitis and gastroenteritis ([@b0075], [@b0130]).

The aim of this study was to evaluate in vitro the antibiotic-modifying activity of menadione in multiresistant strains of *S. aureus*, *P. aeruginosa* and *E. coli*, with gradual increase in its subinhibitory concentration. Also, menadione was compared to cholesterol and ergosterol with regard to mechanism of modulating action (see [Figure 1](#f0005){ref-type="fig"}, [Figure 2](#f0010){ref-type="fig"}).

2. Experimental {#s0010}
===============

2.1. Bacterial material {#s0015}
-----------------------

Bacteria used in the minimal inhibitory concentration (MIC) test were the standard strains of *S. aureus* ATCC 25923, *P. aeruginosa* ATCC 15442 and *E. coli* ATCC 10536. To evaluate the modulatory activity of the extract, the following multi-resistant bacterial strains were used, isolated from clinical environments: *P. aeruginosa* 03, *E. coli* 27 and *S. aureus* 358, with the resistance profile demonstrated in [Table 1](#t0005){ref-type="table"} in the MIC test. All strains were obtained from the Laboratory of Clinical Mycology -- UFPB. All strains were maintained on heart infusion agar slants (HIA, Difco Laboratories. Lawrence, USA) and prior to assay, the cells were grown overnight at 37 °C in brain heart infusion (BHI, Difco Laboratories, Lawrence, USA).

2.2. Drugs {#s0020}
----------

### 2.2.1. Liposoluble vitamins {#s0025}

The vitamin K3 (Menadione) was obtained from Sigma Chemical Co., St. Louis, USA. Stock solutions were prepared in 1 mL of dimethylsulfoxide (DMSO), at a concentration of 100 mg/mL, after which they were diluted to a concentration of 1024 μg/mL in distilled water, except menadione which was diluted in DMSO. Thus, a DMSO control was included to determine any possible interference with the results.

### 2.2.2. Sterols {#s0030}

Cholesterol and ergosterol were obtained from Sigma Chemical Co., St. Louis, USA. Stock solutions were prepared in 2 mL of DMSO/Tween 80 at a concentration of 200 mg/mL, after which they were diluted to 1024 μg/mL in distilled water.

### 2.2.3. Antibiotics {#s0035}

Drugs used in the tests were the aminoglycosides amikacin, neomycin and gentamicin (Sigma Co., St. Louis, USA). All drugs were diluted in sterile water, to a concentration of 5000 μg/mL.

2.3. Antibacterial and modulatory activity {#s0040}
------------------------------------------

The minimal inhibitory concentration (MIC) was determined by the broth microdilution assay. MIC is defined as the lowest concentration at which no microbial growth is observed. MIC was determined using a bacterial suspension of 10^5^ CFU/mL in 10% brain heart infusion (BHI) broth. In 96-well microdilution plates, 100 mL of inoculum were added to each well followed by 100 mL of a serially diluted solution of menadione, cholesterol or ergosterol starting at a concentration of 1024 μg/mL. The final concentrations varied from 1024 to 8 μg/mL. The plates were incubated for 24 h at 35 °C ([@b0030]). The potential of the vitamin, cholesterol and ergosterol as modifiers of antibacterial resistance was determined as proposed by [@b0010] with modifications. The solution of vitamin was tested at three subinhibitory concentrations (MIC/8, MIC/4 and MIC/2). In a microdilution plate, 100 mL of BHI with bacterial inoculum and liposoluble vitamins were added to each well, and 100 mL of antimicrobial drugs were then serially diluted 1:2 with concentrations varying 1024--0.5 μg/mL. The plates were incubated for 24 h at 37 °C.

3. Results and discussion {#s0045}
=========================

This is the first report of antibacterial activity and potentiation of menadione by the aminoglycosides, against multiresistant bacteria. Until now, there had been no report on the use of menadione as a modulator of antibiotics.

In view of the development of bacterial resistance to antibiotics, which is responsible for the lack of efficacy in the treatment of many existing infections, the pharmaceutical industry, in recent years, has shown increased interest in substances isolated from natural products that possess antimicrobial properties ([@b0045], [@b0055], [@b0120]).

Menadione demonstrated antibacterial activity against *P. aeruginosa* 03, with a MIC of 64 μg/mL, while DMSO, used as a negative control, showed a much higher MIC of 256 μg/mL against the strain tested. Menadione showed no significant antibacterial activity against the other bacterial strains analyzed, where MIC was the same as the DMSO control ([Table 2](#t0010){ref-type="table"}). Dimethylsulfoxide is versatile and has several pharmacological and therapeutic properties, including antimicrobial action, showing in vitro bactericidal or bacteriostatic activity at concentrations of 5--50% against various pathogenic bacteria, including *Staphylococcus* spp., *E. coli*, *Mycobacterium tuberculosis*, *Streptococcus* spp., *Salmonella* spp. and *Proteus* spp. ([@b0005], [@b0115], [@b0070]).

Lipophilic substances and menadione cause disturbances in the bacterial membrane, resulting in damage of the fundamental elements needed for membrane integrity, such as reduced membrane potential and loss of ions, cytochrome C, proteins and radicals, followed by the collapse of the proton pump and ATP depletion ([@b0110], [@b0135], [@b0025]). Permeabilization of the outer and inner membrane can subsequently occur and facilitate the entry of antibiotics, causing cell lysis and death ([@b0040]).

When combined with the aminoglycoside class of antibiotics, menadione decreased the antibiotic MIC with increasing subinhibitory concentration of vitamin K3, MIC/8 to MIC/2, indicating a synergistic relationship ([Table 3](#t0015){ref-type="table"}).

Menadione at the subinhibitory concentration of MIC/8 did not show antibiotic-modifying potential in any of the bacterial strains used. Subinhibitory concentration MIC/4 showed a significant synergistic interaction in *S. aureus* 358 with amikacin and neomycin and *E. coli* 27 with all aminoglycosides. Subinhibitory concentration MIC/2 was synergistic with all antibiotics and strains tested, including *P. aeruginosa* 03.

Especially notable is that menadione was significantly effective against *S. aureus* 358 and mainly *E. coli* 27, microorganisms with different morphologies. Gram-positive *S. aureus* has a thick and rigid cell wall formed by layers of peptidoglycan. The cell walls of Gram-negative bacteria such as *E. coli* contain only a thin peptidoglycan layer ([@b0130]), which suggests that menadione, due to its lipid-soluble nature has a lipophilic action on the bacterial cell envelope, causing a disruption of the fluid mosaic membrane ([@b0085]), affecting *E. coli* more so than *S. aureus*.

According to [@b0080] Gram-positive and Gram-negative bacteria are more sensitive to low-polarity compounds due to the presence of polysaccharide chains in the bacterial membrane that act as barriers to hydrophobic substances.

Ergosterol and cholesterol are major components of biological membranes of eukaryotes, where they control permeability, but they are absent in the membrane of bacteria. The cell can control its fluidity by regulating the level of cholesterol, or the saturation of phospholipid hydrocarbon chains ([@b0015]). Due to their lipophilic structure, analogous to menadione, both were used as controls to check and compare the mechanism of action of menadione in the bacterial membrane.

Cholesterol and ergosterol had no antimicrobial activity, showing MIC ⩾1024 μg/mL, which was already expected. However, the combination of either with antibiotics, against multiresistant bacteria, reduced the antibiotic MIC significantly as the subinhibitory concentration of the sterols was increased ([Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}). There is no previous report on the use of cholesterol and ergosterol as modifiers of the action of antibiotics or any other drug, so this is the first study in this area. Thus, it was possible to determine the similarity between menadione between cholesterol, and ergosterol with regard to antibiotic-modifying activity.

4. Conclusion {#s0050}
=============

Menadione demonstrated clinically relevant results in the modulation of aminoglycosides against multiresistant bacteria. This represents an interesting alternative to increasing bacterial resistance, since menadione is present in the diet, and is not toxic to humans. Pre-clinical and clinical studies are warranted to determine bioavailability and mechanisms of action involved in this interaction.
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###### 

Bacterial resistance profile against antibiotics.

  Bacterial strain                      Source           Resistance profile
  ------------------------------------- ---------------- -----------------------------------------------------------------------------
  *Staphylococcus aureus* SA 358        Surgical wound   Oxa, Gen, Tob, Ami, Can, Neo, Para, But, Sis, Net
  *Staphylococcus aureus* ATCC 25923    --               --
  *Escherichia coli* EC27               Surgical wound   Ast, Ax, Amp, Ami, Amox, Ca, Cfc, Cf, Caz, Cip, Clo, Im, Can, Szt, Tet, Tob
  *Escherichia coli* ATCC 10536         --               --
  *Pseudomonas aeruginosa* PA03         Catheter tip     Cpm, Ctz, Im, Cip, Ptz, Lev, Mer, Ami
  *Pseudomonas aeruginosa* ATCC 15442   --               --

Ast -- Aztreonam; Ax -- Amoxacillin; Amp -- Ampicillin; Ami -- Amikacin; Amox -- Amoxicillin; Ca -- Cefadroxil; Cfc -- Cefaclor; Cf -- Cephalothin; Caz -- Ceftazidime; Cip -- Ciprofloxacin; Clo -- Chloramphenicol; Im -- Imipenem; Can -- Kanamycin; Szt -- Sulphametrophim, Tet -- Tetracycline; Tob -- Tobramycin; Oxa -- Oxacillin; Gen -- Gentamicin; Neo -- Neomycin; Para -- Paramomicin; But -- Butirosin; Sis -- Sisomicin; Net -- Netilmicin; (--) absence of resistance or non-significant resistance.

###### 

Minimum inhibitory concentration (MIC) of menadione (vitamin K3) against bacterial strains.

  Bactérias                 MIC (μg/mL)   
  ------------------------- ------------- -----
  *S. aureus*               128           128
  *P. aeruginosa*           64            256
  *Klebsiella pneumoniae*   128           128
  *E. coli*                 128           128

###### 

Antibiotic modulatory activity of menadione alone or associated with aminoglycosides in sub-inhibitory concentrations (MIC/8, MIC/4 and MIC/2).

  Menadione (vitamin K) (μg/mL)                                                              
  ------------------------------- ------- ------- ------- ------ ------ ------- ----- ------ -------
  *Staphylococcus aureus* 358                                                                
  Amikacin                        78.1    39.1    39.1    9.7    19.5   78.1    2.4   9.7    156.2
  Gentamicin                      9.7     78.1    4.8     2.4    2.4    2.4     2.4   2.4    312.5
  Neomycin                        156.2   156.2   156.2   2.4    4.8    156.2   2.4   2.4    156.2
                                                                                             
  *Pseudomonas aeruginosa* 03                                                                
  Amikacin                        156.2   156.2   156.2   39.1   39.1   78.1    2.4   9.7    312.5
  Gentamicin                      39.1    39.1    39.1    9.7    19.5   19.5    2.4   2.4    625
  Neomycin                        156.2   78.1    78.1    78.1   78.1   78.1    2.4   78.1   78.1
                                                                                             
  *Escherichia coli* 27                                                                      
  Amikacin                        78.1    156.2   156.2   9.7    78.1   78.1    2.4   4.8    156.2
  Gentamicin                      19.5    19.5    39.1    2.4    19.5   9.7     2.4   2.4    625
  Neomycin                        78.1    2.4     312.5   78.1   78.1   312.5   2.4   4.8    312.5

###### 

Antibiotic modulatory activity of cholesterol alone or associated with aminoglycosides in sub-inhibitory concentrations (MIC/8, MIC/4 and MIC/2).

  Cholesterol (μg/mL)                                                   
  ----------------------------- ------- ------- ------- ------- ------- -------
  *Staphylococcus aureus* 358                                           
  Amikacin                      78.1    39.1    39.1    19.5    19.5    156.2
  Gentamicin                    4.8     19.5    2.4     2.4     2.4     9.7
  Neomycin                      39.1    156.2   4.8     78.1    9.7     156.2
                                                                        
  *Pseudomonas aeruginosa* 03                                           
  Amikacin                      78.1    39.1    156.2   156.2   39.1    78.1
  Gentamicin                    19.5    39.1    39.1    39.1    4.8     19.5
  Neomycin                      156.2   312.5   156.2   312.5   156.2   156.2
                                                                        
  *Escherichia coli* 27                                                 
  Amikacin                      39.1    39.1    19.5    78.1    39.1    156.2
  Gentamicin                    9.7     9.7     2.4     4.8     4.8     9.7
  Neomycin                      156.2   156.2   78.1    156.2   78.1    78.1

###### 

Antibiotic modulatory activity of ergosterol alone or associated with aminoglycosides in sub-inhibitory concentrations (MIC/8, MIC/4 and MIC/2).

  Ergosterol (μg/mL)                                                   
  ----------------------------- ------- ------- ------ ------- ------- -------
  *Staphylococcus aureus* 358                                          
  Amikacin                      78.1    39.1    9.7    19.5    19.5    156.2
  Gentamicin                    4.8     19.5    2.4    2.4     2.4     9.7
  Neomycin                      19.5    156.2   39.1   78.1    78.1    156.2
                                                                       
  *Pseudomonas aeruginosa* 03                                          
  Amikacin                      78.1    39.1    39.1   156.2   19.5    78.1
  Gentamicin                    4.8     39.1    9.7    39.1    4.8     19.5
  Neomycin                      312.5   312.5   625    312.5   156.2   156.2
                                                                       
  *Escherichia coli* 27                                                
  Amikacin                      39.1    39.1    9.7    78.1    9.7     156.2
  Gentamicin                    9.7     9.7     2.4    4.8     2.4     9.7
  Neomycin                      156.2   156.2   39.1   156.2   39.1    78.1
